JW LIFESCIENCE CORPORATION
Financials
Valuation Metrics
JW LIFESCIENCE CORPORATION's Market Cap is ₩1686B. At end of 2025 it was ₩2035B. Ranked #902 of 2,410 in KR market (top 37%), #482 of 779 on KOSPI (top 62%), #105 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 45%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 168.64B KRW | KR#902/2,410 Sec#105/231 |
| Revenue | 253.71B KRW | KR#906/2,410 Sec#46/231 |
| Net Income | 26.02B KRW | KR#605/2,410 Sec#36/231 |
| Total Assets | 305.78B KRW | KR#1,025/2,410 Sec#68/231 |
| Net Assets | 226.76B KRW | KR#878/2,410 Sec#61/231 |
| Employees | 328 | KR#738/2,410 Sec#64/231 |
| Value | ||
| P/E | 6.48x | KR#581/2,410 Sec#24/231 |
| P/B | 0.74x | KR#1,261/2,410 Sec#75/231 |
| P/S | 0.66x | KR#1,165/2,410 Sec#56/231 |
| EV/EBITDA | 5.70x | KR#320/2,410 Sec#8/231 |
| FCF Yield | 16.59% | KR#425/2,410 Sec#9/231 |
| Profitability | ||
| ROE | 11.47% | KR#511/2,410 Sec#36/231 |
| ROA | 8.51% | KR#395/2,410 Sec#29/231 |
| Op. Margin | 13.14% | KR#363/2,410 Sec#33/231 |
| Revenue Growth | 4.13% | KR#1,248/2,410 Sec#127/231 |
| Earnings Growth | -47.42% | KR#1,048/2,410 Sec#69/231 |
| Financial Health | ||
| Debt Ratio | 34.85% | KR#688/2,410 Sec#85/231 |
| Total Debt | 30.50B KRW | KR#1,220/2,410 Sec#93/231 |
| FCF | 27.98B KRW | KR#430/2,410 Sec#23/231 |
| Cash | 9.00B KRW | KR#1,750/2,410 Sec#154/231 |
| Current Ratio | 1.25x | KR#1,441/2,410 Sec#152/231 |
| Net Debt/EBITDA | 0.64x | KR#698/2,410 Sec#44/231 |
| Dividend | ||
| Div. Yield | 5.16% | KR#303/2,410 Sec#10/231 |
| Div. Growth | 10.00% | KR#598/2,410 Sec#33/231 |
| Performance | ||
| 1Y Return | -20.82% | KR#1,177/2,410 Sec#80/231 |
| 1M Return | -3.45% | KR#640/2,410 Sec#67/231 |
| From 52W High | -31.64% | KR#454/2,410 Sec#30/231 |
| 1Y MDD | -32.77% | KR#319/2,410 Sec#23/231 |
| Trading | ||
| Volume | 6,094 shares | KR#1,776/2,410 Sec#179/231 |
| Trading Value | 64.6M KRW | KR#1,380/2,410 Sec#144/231 |
| Foreign Own. | 14.47% | KR#334/2,410 Sec#21/231 |
| Per Share | ||
| EPS | 1,643 KRW | KR#518/2,410 Sec#36/231 |
| BPS | 14,321 KRW | KR#728/2,410 Sec#48/231 |
Company Info
Established in 1994, this company produces and sells professional pharmaceutical infusions, including 3-Chamber nutritional infusions, which are manufactured by only a few companies. It has signed licensing-out and export contracts with global infusion manufacturer Baxter Corporation, becoming the first in Asia to obtain EU-GMP certification for its TPN production facility, recognizing its world-class production infrastructure. The HP Research Center is pursuing global growth through the development of non-PVC materials and the launch of TPN products, leveraging infusion-related technologies. JW Life Science is headquartered in Dangjin, Chungcheongnam-do.